IPG 11406
Alternative Names: IPG-11406Latest Information Update: 13 Dec 2024
Price :
$50 *
At a glance
- Originator Immunophage Biotech
- Class Anti-inflammatories; Antibodies; Antirheumatics; Small molecules
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 05 Dec 2024 Nanjing Immunophage Biotech plans to initiate a phase I/II trial for Lupus Nephritis in China (PO) (NCT06717815)
- 13 Feb 2024 Nanjing Immunophage Biotech plans a phase I trial for Inflammatory bowel diseases (In volunteers) in China in February 2024 (PO, Tablet) (NCT06255834)
- 06 Feb 2024 Preclinical data released by Immunophage Biotech (Immunophage Biotech website, January 2024)